ArticleJournal of natural products2015
Cytotoxic activity of rearranged drimane meroterpenoids against colon cancer cells via down-regulation of β-catenin expression.
Article in Journal of natural products, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Amides Derived From Sclareolide as Cytotoxic Agents.Chemistry & biodiversity · 2026Article
- Bioactive Terpenes from Marine Sponges and Their Associated Organisms.Marine drugs · 2025Review
- GenusMolecules (Basel, Switzerland) · 2022Review
- Chemical and biological diversity of new natural products from marine sponges: a review (2009-2018).Marine life science & technology · 2022Review
- Biological activities of meroterpenoids isolated from different sources.Frontiers in pharmacology · 2022Review
- An Overview of Bioactive 1,3-Oxazole-Containing Alkaloids from Marine Organisms.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Application of Networking Approaches to Assess the Chemical Diversity, Biogeography, and Pharmaceutical Potential of Verongiida Natural Products.Marine drugs · 2021Article
- Marine natural products from sponges (Porifera) of the order Dictyoceratida (2013 to 2019); a promising source for drug discovery.RSC advances · 2020Review
- Natural Nitrogenous Sesquiterpenoids and Their Bioactivity: A Review.Molecules (Basel, Switzerland) · 2020Review
- Divergent synthesis of chiral cyclic azides via asymmetric cycloaddition reactions of vinyl azides.Nature communications · 2019Article
- Sesterterpenoid and Steroid Metabolites from a Deep-Water Alaska Sponge Inhibit Wnt/β-Catenin Signaling in Colon Cancer Cells.Marine drugs · 2018Article
- Bioactive Prenyl- and Terpenyl-Quinones/Hydroquinones of Marine OriginMarine drugs · 2018Review
- In silico investigation of lavandulyl flavonoids for the development of potent fatty acid synthase-inhibitory prototypes.Biochimica et biophysica acta. General subjects · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Colorectal cancer has emerged as a major cause of death in Western countries. Down-regulation of β-catenin expression has been considered a promising approach for cytotoxic drug formulation. Eight 4,9-friedodrimane-type sesquiterpenoids (1-8) were acquired using the oxidative potential of Verongula rigida on bioactive metabolites from two Smenospongia sponges. Compounds 3 and 4 contain a 2,2-dimethylbenzo[d]oxazol-6(2H)-one moiety as their substituted heterocyclic residues, which is unprecedented in such types of meroterpenoids. Gauge-invariant atomic orbital NMR chemical shift calculations were employed to investigate stereochemical details with support of the application of advanced statistics such as CP3 and DP4. Compounds 2 and 8 and the mixture of 3 and 4 suppressed β-catenin response transcription (CRT) via degrading β-catenin and exhibited cytotoxic activity on colon cancer cells, implying that their anti-CRT potential is, at least in part, one of their underlying antineoplastic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.